|
|
|
市場調查報告書
神經變異性疾病治療藥
Neurodegenerative Drugs
|
神經變異性疾病治療藥 是由出版商Global Industry Analysts, Inc.在2010年04月所出版的。
這份英文市場調查報告書包含Pages: 1108 價格從美金3950起跳。
本報告書為全球神經變性疾病治療藥市場的相關分析，包含阿茲海默症，巴金森症、多發性硬化症等各領域概要與治療藥動向，以及涉足市場的主要企業概要與各國各市場動向交之而成，概述如下。
第1章 導論、調査方法、產品定義
第2章 總綱
- 全球市場概要
- 世界市場分析
- 各疾病市場分析
- 神經變性疾病治療藥
- 阿茲海默症以及巴金森症市場
- 市場影響因子
- 關注在神經變性疾病的神經科學研究
- 神經科學研究的進歩
- 神經變性疾病市場評論
- 阿茲海默症市場
- 巴金森症市場
- 多發性硬化症市場
- 肌肉萎縮性側索硬化症市場
- 亨丁頓舞蹈症市場
- 神經因性疼痛市場
- 庫賈氏症
- 將來的治療法
- 阿茲海默症市場
- 巴金森症市場
- 多發性硬化症市場
- 肌肉萎縮性側索硬化症市場
- 神經變性疾病概要
- 神經變性
- 神經變性疾病的相關要因概要
- 神經變性疾病概要
- 神經變性疾病治療藥概要
- 神經變性疾病研究
- 實驗
- 產品導入／認可／開發
- 近年的業界活動
- 主要企業
- 世界市場前景
第3章 市場
第4章 競爭環境
Abstract
This report analyzes the worldwide markets for Neurodegenerative Drugs in US$
Million by the following disease types: Alzheimer' s Disease, Parkinson' s
Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other
Neurodegenerative Diseases. The report provides separate comprehensive
analytics for the US, Europe, and Rest of World. Annual estimates and
forecasts are provided for each region for the period 2006 through 2015. The
report profiles 165 companies including many key and niche players such as
Amarin Corporation PLC, AstraZeneca PLC, Avanir Pharmaceuticals, Inc., Avigen,
Inc., Bayer Schering Pharma AG, Boehringer Ingelheim GmbH, Biogen Idec Inc.,
Bristol-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc.,
Elan Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Inc.,
GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Merck Serono
SA, Mitsubishi Tanabe Pharma Corporation, Neurologix, Inc., NeuroSearch A/S,
Novartis AG, Pfizer, Inc., Sanofi-aventis S.A, Shire Pharmaceuticals Group
PLC, Teva Pharmaceutical Industries Limited, Valeant Pharmaceuticals
International, and Wyeth Pharmaceuticals, Inc. Market data and analytics are
derived from primary and secondary research. Company profiles are mostly
extracted from URL research and reported select online sources.
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
- Alzheimer' s Disease
- Parkinson' s Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Others
- Huntington' s Disease
- Neuropathic Pain
- Prion Disease
II. EXECUTIVE SUMMARY
1. GLOBAL MARKET OVERVIEW
- Global Market Analysis
- Global Market Analysis by Disease Type
- Neurodegenerative Drugs - The Next Big Thing in Healthcare
- Alzheimer' s and Parkinson' s Market
- Factors Affecting the Market
- Major Growth Drivers Ahead
- Major Growth Inhibitors
- Rapid Growth of Aging Population
- Table 1: Global 65+ Age Group Population in Millions (includes
corresponding Graph/Chart)
- Higher Alzheimer' s and Parkinson' s Prevalence
- Price Hikes and Government Caps
- Future Holds Promise!
- Research & Development
- Neuroscience Research Focused on Neurodegenerative Diseases
- Neuroscience Research Advances to Make a Mark...
- Summary of Major Neuroscience Research Developments in 2009
2. A REVIEW OF SELECT NEURODEGENERATIVE DRUGS MARKETS
- A. Alzheimer' s Market in Review
- The AD Epidemiology
- Table 2: World Alzheimer' s Disease Prevalence by Country/Region: Number
of Patients in US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain
and Rest of Europe), Asia-Pacific (Australia, India, Philippines and Rest of
Asia-Pacific), Brazil and Rest of World in Thousands for Years 2001 through
2010 (includes corresponding Graph/Chart)
- Table 3: Alzheimer' s Disease Statistics in Top Seven Countries (US,
Japan, Germany, France, UK, Italy and Spain): Number of Patients Diagnosed
and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage)
in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)
- The Impact of Dementia
- A Look At AD Demographics
- A Global Overview
- Geographic Overview
- Growth Drivers
- Aging Baby Boomers - The Market' s Growth Engine
- Table 4: AD Frequency Rates in the US and Europe: Percentage Share by
Age Group (includes corresponding Graph/Chart)
- Unmet Medical Needs Drive Market Growth
- Growth Restrains
- Misdiagnosis
- Lack of Awareness
- High Cost of Treatment
- Market Outlook for Anti-AD Drugs
- Cholinesterase Inhibitors - The Leader, but Not Strong Growth Contender
- NMDA Receptor Antagonists - Dynamic Growth Potential, Albeit A Small Base
- Approval of Anti-AD Drugs (Cholinesterase Inhibitors) in Select Countries
- Competitive Landscape
- B. The Parkinson' s Market in Review
- The PD Epidemiology
- Table 5: World Parkinson' s Disease Prevalence by Country/Region: Number
of Patients in the US, Canada, Japan, Europe (Germany, France, UK, Italy,
Spain and Rest of Europe), China and Rest of World in Thousands for Years
2001 through 2010 (includes corresponding Graph/Chart)
- A Global Overview
- Dominance of Dopamine Agonists
- Stalevo Continues to Outshine
- The Slippery Path to Clinical Success
- Market Drivers
- Emergence of Dopamine Agonists as First Line Treatment
- The Debut of Stalevo
- High Unmet Clinical Needs
- Market Inhibitors
- Lack of Awareness and Under-diagnosis
- Limitations of Existing Medicines
- Restricted Period Use of Dopamine Agonists
- Generic Competition from L-Dopa and Carbidopa
- C. The Multiple Sclerosis Market in Review
- The MS Epidemiology
- Table 6: World Multiple Sclerosis Prevalence in Thousands by Select
Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Facts About Multiple Sclerosis
- Market Overview
- Interferon-based Drugs Lead Multiple Sclerosis Drugs Market
- High Unmet Need and Rich Pipeline to Expand MS Market
- Sales Dip Inevitable for Current Therapies
- Tough Times Ahead for Betaseron
- Competitive Landscape
- Table 7: Global Multiple Sclerosis Market by Leading Drugs (2008 &
2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron,
and Tysabri (includes corresponding Graph/Chart)
- D. The ALS Market in Review
- The ALS Epidemiology
- Market Overview
- Sanofi-aventis - The ALS Drugs Market Leader
- E. The Huntington' s Market in Review
- The HD Epidemiology
- Market Outlook
- F. Neuropathic Pain Market in Review
- G. Prion Disease
3. FUTURE THERAPIES
- Alzheimer' s Disease
- Select Pipeline Drugs for Alzheimer' s Disease
- Parkinson' s Disease
- Select Pipeline Drugs for Parkinson' s Disease
- Huntington' s Disease
- Select Pipeline Drugs for Treatment of Huntington' s Disease
- Multiple Sclerosis
- Oral Pipeline Drugs to Alter Market Dynamics in MS Therapies
- Select Pipeline Drugs for Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Select Pipeline Drugs for Amyotrophic Lateral Sclerosis
4. NEURODEGENERATIVE DISEASES OVERVIEW
- Neurodegeneration
- An Overview of Factors that Link Neurodegenerative Diseases
- Genetics
- Intracellular Mechanisms
- Protein Degradation Pathways
- Mitochondrial Dysfunction
- Axonal Transport
- Programmed Cell Death
- An Overview of Select Major Neurodegenerative Diseases
- Alzheimer' s Disease
- Definition
- Cause
- Diagnoses
- Prevention
- Treatment
- Anti-AD Drug Classes and Approved Products
- Parkinson' s Disease
- Definition
- Cause
- Diagnosis
- Therapeutic Treatment
- List of Drugs Available for the Treatment of Parkinson' s Disease
- Surgical Intervention
- Multiple Sclerosis
- Definition
- Types of Multiple Sclerosis
- Table 8: Prevalence of Different Types of Multiple Sclerosis (includes
corresponding Graph/Chart)
- Etiology
- Pathology
- Treatment
- List of Approved Multiple Sclerosis Drugs
- Huntington' s Disease
- Definition
- Prognosis
- The Three Stages of HD
- Symptoms and Signs
- List of Physical, Psychiatric and Cognitive Symptoms in Huntington' s
Disease
- Diagnosis
- Treatment
- Amyotrophic Lateral Sclerosis (ALS)
- Definition
- Types of ALS
- Familial ALS
- Sporadic ALS
- Guamanian ALS
- Etiology
- Symptoms
- Diagnosis
- Treatment
5. AN OVERVIEW OF NEURODEGENERATIVE DRUGS FOR SELECT DISEASES
- Neurodegenerative Drugs for Alzheimer' s Disease
- NMDA Receptor Antagonists (NMDARA)
- Memantine
- Cholinesterase Inhibitors (ChEIs)
- Donepezil (Aricept)
- Rivastigmine (Exelon)
- Galantamine Hydrobromide (Razadyne)
- Tacrine (Cognex)
- Other Alternatives
- Vitamin E
- Estrogen Therapy
- NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
- Gingko Biloba
- Neurodegenerative Drugs for Parkinson' s Disease
- Dopaminergic Agents
- Levodopa/Carbidopa
- Dopamine Agonists
- Bromocriptine/Parlodel
- Ropinirole/Requip
- Pramipexole/Mirapex
- Cabergoline/Dostinex
- Apomorphine/Apokyn
- Other PD Drugs
- COMT Inhibitors
- MAO-B Inhibitors
- Dopamine Amplifiers
- Anticholinergics
- Neurodegenerative Drugs for Huntington' s Disease
- Tetrabenazine
- Others
- Neurodegenerative Drugs for Multiple Sclerosis
- Interferon Drugs
- Beta Interferon Drugs for the Treatment of Multiple Sclerosis
- Non-Interferon Drugs
- Non-Interferon Drugs for the Treatment of Multiple Sclerosis
- Neurodegenerative Drugs for Amyotrophic Lateral Sclerosis
- Rilutek
- Symptomatic Treatment
6. NEURODEGENERATIVE RESEARCH
- Neurologix' s Non-dopamine Gene Therapy for PD
- Cell Cure' s Cell Replacement Therapy for PD
- Researches Developing Neuroprotective Agent for PD
- UT Southwestern Researchers Study New Compound for HD
- UCLA Scientists Identify Molecular Switch Capable of Blocking HD
- Repligen Reports Detection of HDAC 3 Drug Target for Friedreich' s Ataxia
(US)
- Tel Aviv University Reports Stem Cell Cure for Neurodegeneration (Israel)
- Cambridge Researchers Develop Novel Drug Targets for HD
- Emory Research Team Develops First Transgenic Monkey Model of HD
- KeyNeurotek Pharma Discloses Molecular Pathomechanism of HD Mutation
- Researchers Identify New Gene for ALS
- Q Therapeutics and Johns Hopkins Research Team to Study GRPs in ALS Model
- ALS TDI and CSC Collaborate to Study Stem Cells Use in ALS Treatment
- Allen Institute and ALS TDI to Conduct ALS Study
- Life Technologies to Develop Neurodegenerative Disease Models
- Neuralstem and University of Michigan Collaborate for ALS Research
- ALS TDI and MDA Collaborate for ALS Drug Discovery
7. SELECT CLINICAL TRIALS
- Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
- Medivation' s Dimebon Fails to Meet End Points in Phase III Trial
- QR Pharma Annuls Phenserine Production
- Neurologix Begins Phase II Studies for Parkinson' s Disease Treatment (US)
- Biovail and ACADIA Complete Phase II Clinical Trials for Pimavanserin
(Canada, US)
- Merck Serono Announces Encouraging Phase III Results of Oral Mylinax
- Alnylam and Medtronic Present New Preclinical Data on ALN-HTT
- NeuroSearch Presents ACR16 as Novel Huntington' s Disease Therapy
- Eli Lilly Launches Two Phase-III Trials for Solanezumab(i) Worldwide (US)
- Teva and Active Biotech Obtains Fast Track Status from FDA for Oral
Laquinimod
- CytRx Initiates Phase II/III Clinical Trial for Arimoclomol
- Synosia Therapeutics Starts Stage-I Clinical Trial for SYN-120
(Switzerland)
- H. Lundbeck Begins Phase-I Clinical Tests for Lu 02-750 (Denmark)
- Anavex Life Sciences Selects FORENAP Pharma EURL for ANAVEX 2-73 Phase-I
Clinical Tests (Switzerland)
- Bayer Schering Pharma Completes Stage-II Trials for BAY 94-9172 (Germany)
- Newron and Merck Serono Start Second Round of Phase III Tests for
Safinamide (Italy)
- Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated
Interferon Beta-1a
- ExonHit Therapeutics Completes Phase-II Clinical Study for EHT 0202
(France)
- Kyowa Hakko Kirin to Start Phase-III Clinical Trials for Istradefylline
in Japan
- Medtronic and Alnylam Pharma Report Pre-Clinical Results of ALN-HTT (US)
- Eli Lilly Begins Phase III Clinical Trial of Alzheimer' s Treatment
- NeuroSearch Begins Critical Phase III Program with ACR16
- Avicena to Proceeds with Phase III Trial of HD-02
- Knopp Neurosciences Commences Phase II Study of KNS- 760704
- Maas Biolab SBIR Initiates Phase II for Cyclosporin
- MediciNova Announces Phase II Clinical Trial Results of MN-166
- Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02
- EnVivo Pharmaceuticals Progresses on Major HDACi Program
- NeuroSearch Files CTA in Europe to Begin Clinical Phase III Program with
ACR16
8. PRODUCT INTRODUCTIONS/ APPROVALS/ DEVELOPMENTS
- Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat
Multiple Sclerosis
- Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
- Accera Introduces Axona™
- Eisai Receives Approval for Aricept®
- Copaxone Receives FDA Approval for Patients with First Clinical Episode
Suggestive of MS
- Copaxone Receives FDA Approval for Patients with First Clinical Episode
Suggestive of MS
- Novartis Obtains FDA Approval for Extavia
- ArmaGen Develops IgG-Decoy Receptor Fusion Protein (US)
- Knopp' s KNS-760704 Receives EC Orphan Designation
- NeuroSearch Receives EMEA Approval for Huntexil™ Brand Name (Europe)
- Cambridge Labs Receives Spanish Marketing Approval for Tetrabenazine
- ArmaGen Technologies Secures Orphan Drug Designation for AGT-181 from FDA
(US)
- Raptor Pharmaceuticals Receives FDA Orphan Drug Designation for Cysteamine
- Elan and Biogen Receive Health Canada Approval for MS Use of Tysabri™
- Exelon Patch Wins EU Approval for Alzheimer' s Treatment
- Isis Pharma Receives Orphan Drug Designation for ISIS333611
9. RECENT INDUSTRY ACTIVITY
- Lundbeck Acquires LifeHealth
- StemCells Acquires Stem Cell Sciences
- Oryzon Takes Over Crystax Pharmaceuticals
- JANSSEN Acquires Elan' s Alzheimer' s Immunotherapy Program
- Hisamitsu Takes Over Noven Pharmaceuticals
- Lundbeck Takes Over Ovation Pharmaceuticals
- Valeant Pharmaceuticals Takes Over Dow Pharmaceutical Sciences
- Genzyme Acquires Assets of Targeted Genetics Corporation
- Merck Takes Over Insmed' s Follow-on Biologics Assets
- NeuroSearch Reacquires Global Rights to ACR16
- Biovail Acquires Worldwide Rights to Tetrabenazine
- Raptor Pharmaceuticals Merges with TorreyPines
- iZumi Bio Merges with Pierian; Forms iPierian, Inc.
- Cell Genesys Merges with BioSante Pharmaceuticals
- CeNeRx BioPharma Secures Marketing and Development Rights for CXB909
- Laureate Pharma and ZZ Biotech Ink Agreement
- QxPharma Limited Signs Agreement with Patheon
- Cambridge Labs Signs New Agreements to Market Xenazine® in North America
- Shire and UCB Ink Agreement
- NeuroNova and Genentech Signs Agreement for VEGF Use in ALS Treatment
- Biovail to Acquire North American Rights to Fipamezole from Santhera
- Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane
- KineMed Collaborates with Bristol-Myers Squibb
- Vitae Pharmaceuticals Collaborates with Boehringer Ingelheim
- Insmed Inks Deal with IDIS to Organize NPPs for IPLEX™
- Genzyme Corp. and Bayer HealthCare Sign Agreement
- CHDI Foundation Inks Agreement with AMRI for Drug Discovery
- Addex Pharmaceuticals Inks Licensing Agreement with Merck
- Acccera Sets Up Neuera Pharmaceuticals
- Evotec Inks Research Agreement with Biogen Idec
- ALS TDI and Asklepios to Develop ALS Therapy Delivery Alternatives
- Evotec Extends Collaboration with Boehringer Ingelheim
- Neuralstem Collaborates to Develop Neural Stem Cell Therapies
- Eisai and Pfizer Ink Agreement
- BioAdvance Invests in TREVENTIS Corp.
- AstraZeneca Announces Milestone Payments to Targacept for AZD3480 Program
- Suven Life Sciences Secures Two Patents in the US
- Eisai Terminates Contract with Nitto Denko Corporation
- MJFF Awards Grants to Targacept
- Metabolic Solutions Receives Grant from Alzheimer' s Drug Discovery
Foundation
- Medical Research Council and Wellcome Trust to Fund Neurodegeneration
Research
- Biovail Acquires Prestwick Pharmaceuticals
- GlaxoSmithKline Acquires Sirtris Pharmaceuticals
- Newron Pharmaceuticals Acquires Hunter-Fleming
- SYGNIS Pharma Purchases Amnestix
- Proximagen Neuroscience Acquires Cambridge Biotechnology
- Teva Acquires Barr Pharmaceuticals
- Eisai Acquires MGI Pharma
- Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in
the US
- Targeted Genetics Acquires Rights to the siRNA Development Program
- Insmed Obtains Royalty-Free Global Rights for IPLEX™
- Pfizer and Serenex Ink Agreement
- Dr. Reddy' s Laboratories Inks Agreement with Sygnis Pharma
- Cambridge Labs Inks and Renews Agreements in Multiple Nations
- CHDI Inked Collaboration Agreements with Galapagos
- Power3 Medical Products and StemTroniX Sign Letter of Intent
- ALS Therapy Development Institute and Allen Institute Ink Agreement
- Yissum Inks Licensing Agreement with Eucalyptus
- GlaxoSmithKline Biologicals Enters into Licensing Agreement with AFFiRiS
- Neurologix and Aegera Therapeutics Ink Licensing Agreement
- Neurobiological Inks Licensing Agreement with BIAR
- Raptor Pharma Forms Collaboration with CHU d' Angers for Phase II Trial
- Amorfix Completes Research Partnership with Biogen Idec
- Apitope Raises Financing for Developing Multiple Sclerosis Compound
- Pipex Pharmaceuticals Changes Corporate Name to Adeona Pharmaceuticals
- MethylGene Terminates Collaboration Agreement with EnVivo Pharmaceuticals
- Varinel Receives Fund from Alzheimer' s Drug Discovery Foundation
- PharmatrophiX Receives Grants from Alzheimer' s Drug Discovery Foundation
- Eisai Acquires Morphotek
- Transition Therapeutics Acquires NeuroMedix
- Merz Licenses Anti-Alzheimer' s Drug Technology from TAU
- Intellect Neurosciences Inks Agreement with CHDI Foundation to Evaluate
Potential of OXIGONTM
- Intellect Signs Licensing Agreement with Immuno- Biological Laboratories
- Boehringer Ingelheim Signs R&D Agreement with Ablynx
- Evotec Teams Up with Boehringer Ingelheim
- Siemens Medical Signs Partnership Agreement with Wyeth
- Pipex Pharma Signs Agreement for Evaluation of COPREXA
- Digilab Receives Notice of Allowance for New Alzheimer' s Biomarker
- Pfizer Joins Forces with Genizon for AD
- Avicena Teams Up with NINDS for Phase III Trial of PD-02
- QSV and Artielle Sign Contract to Produce RTL-1000 (To be added to Canada)
- ALS TDI Selects Microbix to Manufacture Adenoviruses
- Maas BiolAB Receives SBIR Grant for ALS Study
10. FOCUS ON SELECT GLOBAL PLAYERS
- Amarin Corporation PLC (Ireland)
- AstraZeneca PLC (UK)
- Avanir Pharmaceuticals, Inc. (US)
- Avigen, Inc. (US)
- Bayer Schering Pharma AG (Germany)
- Boehringer Ingelheim GmbH (Germany)
- Biogen Idec Inc. (US)
- Bristol-Myers Squibb Co. (USA)
- Biovail Corporation (Canada)
- Ceregene, Inc. (US)
- Eisai, Inc. (USA)
- Elan Pharmaceuticals (US)
- Eli Lilly and Company (USA)
- Forest Laboratories, Inc. (US)
- GlaxoSmithKline PLC (UK)
- H. Lundbeck A/S (Denmark)
- Merz Pharmaceuticals GMBH (Germany)
- Merck Serono SA (Switzerland)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Neurologix, Inc. (US)
- NeuroSearch A/S (Denmark)
- Novartis AG (Switzerland)
- Pfizer, Inc. (US)
- Sanofi-aventis S.A (France)
- Shire Pharmaceuticals Group PLC (UK)
- Teva Pharmaceutical Industries Limited (Israel)
- Valeant Pharmaceuticals International (US)
- Wyeth Pharmaceuticals, Inc. (US)
11. GLOBAL MARKET PERSPECTIVE
- Analytics by Geographic Region
- Table 9: World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Geographic Region - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 10: World 10-Year Perspective for Neurodegenerative Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and
Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding
Graph/Chart)
- Analytics by Disease Type
- Table 11: World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Disease Type - Alzheimer' s Disease, Parkinson' s
Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others Markets
Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart)
- Table 12: World 10-Year Perspective for Neurodegenerative Drugs by Disease
Type - Percentage Breakdown of Dollar Sales for Alzheimer' s Disease,
Parkinson' s Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and
Others for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
- A. Market Analysis
- Current & Future Analysis
- AD Market Overview
- Approval of Cholinesterase Inhibitors for MCI to Drive Market
- Status of AD Drugs
- Prevalence
- Table 13: US Prevalence of Alzheimer' s Disease for 2005-2010 (includes
corresponding Graph/Chart)
- PD Market Overview
- Levodopa/Carbidopa on Declining Spree
- Patent Expiry Status
- Patent Expiry Status of Parkinson' s Disease Drugs in the US
- Prevalence
- Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market
- Clinical Trials
- Product Launches
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 14: US Recent Past, Current and Future Analysis for
Neurodegenerative Drugs Market - Annual Sales Figures in US$ Million for
Years 2006 through 2015 (includes corresponding Graph/Chart)
2. EUROPE
- A. Market Analysis
- Current & Future Analysis
- Alzheimer' s and Parkinson' s Prevalence in Europe
- Table 15: European Alzheimer' s Disease Prevalence by Country/Region:
Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe
in Thousands For Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 16: European Parkinson' s Disease Prevalence by Country/Region:
Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe
in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)
- Table 17: Multiple Sclerosis Prevalence in Select European Countries for
Years 2001 through 2010 (includes corresponding Graph/Chart)
- Low Penetration to Fuel Growth in European MS DMDs Market
- Clinical Trials
- Product Launches/Approvals
- Strategic Corporate Developments
- Key Players
- B. Market Analytics
- Table 18: European Recent Past, Current and Future Analysis for
Neurodegenerative Drugs by Country/ Region - France, Germany, Italy, UK and
Rest of Europe Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
- Table 19: European 10-Year Perspective for Neurodegenerative Drugs by
Country/Region - Percentage Breakdown of Dollar Sales for France, Germany,
Italy, UK and Rest of Europe Markets for Years 2006, 2009 and 2015 (includes
corresponding Graph/Chart)
3. REST OF WORLD
- A. Market Analysis
- Current & Future Analysis
- Canada - High Prevalence Rates for Multiple Sclerosis
- Table 20: Multiple Sclerosis Prevalence in Canada For Years 2001 through
2010 (includes corresponding Graph/Chart)
- Incidence of Multiple Sclerosis on the Rise in India
- Table 21: Multiple Sclerosis Prevalence in India For Years 2001 through
2010 (includes corresponding Graph/Chart)
- Alzheimer' s and Parkinson' s Prevalence in Canada
- Table 22: Alzheimer' s and Parkinson' s Diseases and Multiple Sclerosis
Prevalence in Canada For Years 2001 through 2010 (includes corresponding
Graph/Chart)
- Alzheimer' s and Parkinson' s Prevalence in Japan
- Table 23: Alzheimer' s and Parkinson' s Diseases Prevalence in Japan for
Years 2001 through 2010 (includes corresponding Graph/Chart)
- Alzheimer' s Prevalence in Asia-Pacific
- Table 24: Alzheimer' s Disease Prevalence in Asia-Pacific by Country:
Number of Patients for Australia, India, Philippines and Rest of
Asia-Pacific in Thousands For Years 2001 through 2010 (includes
corresponding Graph/Chart)
- Clinical Trials
- Research Studies/Other Developments
- Product Launches/Approvals
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 25: Rest of World Recent Past, Current and Future Analysis for
Neurodegenerative Drugs Market - Annual Sales in US$ Million for Years 2006
through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
|
 |
